Diabetic Nephropathy Market Size, Share, Growth Analysis, By Type(Pharmaceutical Therapy, and Renal Replacement Therapy.), By Application(Hospitals, Specialty Clinics, and Others), By Diagnostic Methods(Blood Tests, Urine Tests, and Imaging Techniques.), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35D2095 | Region: Global | Published Date: February, 2024
Pages: 157 |Tables: 89 |Figures: 76

Diabetic Nephropathy Market Insights

Diabetic Nephropathy Market size was valued at USD 2.01 billion in 2022 and is poised to grow from USD 2.13 billion in 2023 to USD 3.40 billion by 2031, growing at a CAGR of 6% in the forecast period (2024-2031).

The global diabetic nephropathy market is experiencing significant growth, driven by the increasing prevalence of diabetes and the rising demand for effective treatment options. One of the primary factors contributing to the growth of the diabetic nephropathy market is the growing diabetic population. Diabetes has reached epidemic proportions globally, with millions of people affected by the disease. As diabetes progresses, the risk of developing diabetic nephropathy increases, creating a substantial patient pool requiring treatment. This rising patient population is propelling the demand for innovative therapies and driving market growth. Moreover, advancements in medical research and technology have led to the development of novel diagnostic tools and treatment options for diabetic nephropathy. Biomarkers and genetic testing methods have improved early detection and risk assessment, enabling timely intervention and disease management. Additionally, the introduction of targeted therapies, such as renin-angiotensin-aldosterone system (RAAS) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors, has shown promising results in slowing the progression of diabetic nephropathy and reducing associated complications. These advancements have increased the overall efficacy of treatments, thereby positively impacting market growth.

Market snapshot - 2024-2031

Global Market Size

USD 1.9 billion

Largest Segment

Pharmaceutical Therapy

Fastest Growth

Pharmaceutical Therapy

Growth Rate

6% CAGR

Global Diabetic Nephropathy By Region ($ Bn)
Country Share for North America Region (%)

To get more reports on the above market click here to Buy The Report

Diabetic Nephropathy Market Segmental Analysis

The global diabetic nephropathy market is segmented on the basis of type, application, diagnostic methods, and region. Based on type, the market can be segmented into pharmaceutical therapy, and renal replacement therapy. Based on application, the market is segmented into hospitals, specialty clinics, and others. By diagnostic methods it can be segmented into blood tests, urine tests, and imaging techniques. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Diabetic Nephropathy By Type

To get detailed analysis on other segments, Request For Free Sample Report

Diabetic Nephropathy Market Regional Insights

North America holds a prominent position in the global diabetic nephropathy market. The region is characterised by well-developed electricity infrastructure, a mature market, and a high level of consumer awareness and engagement. The US and Canada are major contributors to the region's dominance, with a strong emphasis on clean energy sources, smart grid systems, and customer-centric retail electricity services. The market in North America is supported by favourable government policies, including incentives for renewable energy adoption and energy efficiency programs. Additionally, the presence of established retail electricity providers and a competitive market landscape contribute to the dominance of North America in the Global Diabetic Nephropathy market.

Asia Pacific is the fastest growing region owing to the robust economic growth, rapid urbanisation, and a rising population, leading to increased energy consumption and demand for electricity. Countries such as China, India, Japan, and South Korea are experiencing significant growth in the retail electricity market. The governments in these countries are focusing on expanding access to electricity, promoting renewable energy sources, and implementing smart grid technologies. Moreover, the increasing adoption of electric vehicles (EVs) in Asia Pacific is driving the demand for retail electricity, as charging infrastructure and services become essential. The fast-growing middle-class population and increasing consumer awareness about clean energy options further contribute to the growth of the retail electricity market in the region

Global Diabetic Nephropathy By Geography
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Diabetic Nephropathy Market Dynamics

Drivers

Increasing Healthcare Expenditure

  • The escalating healthcare expenditure, particularly in emerging economies, significantly contributes to the expansion of the diabetic nephropathy market. Increased healthcare funding enables enhanced accessibility to healthcare facilities, diagnostics, medications, and treatment options for individuals with diabetic nephropathy.

Request Free Customization of this report to help us to meet your business objectives.

Diabetic Nephropathy Market Competitive Landscape

The global diabetic nephropathy market is characterised by intense competition among key players aiming to capture a significant market share. Diabetic nephropathy refers to kidney damage caused by diabetes, and the market encompasses a wide range of treatment options, including medications, dialysis, and kidney transplant. This competitive landscape provides a general overview of the market dynamics without mentioning any specific company names.

Top Player’s Company Profiles

  • Novartis AG (Switzerland)
  • Johnson & Johnson (US)
  • Sanofi S.A. (France)
  • AstraZeneca PLC (United Kingdom)
  • AbbVie Inc. (US)
  • Eli Lilly and Company (US)
  • Bristol Myers Squibb Company (US)
  • GlaxoSmithKline PLC (United Kingdom)
  • Novo Nordisk A/S (Denmark)
  • Bayer AG (Germany)
  • Amgen Inc. (US)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Astellas Pharma Inc. (Japan)
  • Daiichi Sankyo Company, Limited (Japan)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Fresenius Medical Care AG & Co. KGaA (Germany)
  • Otsuka Pharmaceutical Co., Ltd. (Japan)

Recent Developments

  • In March 2023, Novartis announced that it had submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for renoprotective effects of sevelamer carbonate, a phosphate binder, for the treatment of diabetic nephropathy.
  • In January 2022, AstraZeneca announced that it had initiated a Phase 2 clinical trial of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for the treatment of diabetic nephropathy.
  • In September 2021, Mitsubishi Tanabe Pharma announced that it had entered into a licensing agreement with Innovent Biologics for the development and commercialization of moxetumomab pasudotox-tdfk, an anti-CD20 antibody-drug conjugate, for the treatment of diabetic nephropathy.
  • In May 2021, Eli Lilly and Company announced that it had initiated a Phase 3 .clinical trial of tirzepatide, a novel GLP-1 receptor agonist and GIP receptor agonist, for the treatment of diabetic nephropathy.In February 2021, Sanofi announced that it had submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for fostamatinib, a novel JAK inhibitor, for the treatment of diabetic nephropathy.

Diabetic Nephropathy Key Market Trends

  • Development of New and More Effective Treatments: The rising cost of healthcare, and the growing demand for personalised medicine stands as key market trends. As the market continues to grow, we can expect to see more innovation in the treatment of diabetic nephropathy, and this innovation is expected to help improve the lives of people with this condition.

Diabetic Nephropathy Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.

According to global diabetic nephropathy market analysis, the increasing prevalence of diabetes and the rising burden of kidney diseases worldwide are the key growth drivers. Diabetic nephropathy, also known as diabetic kidney disease, is a common complication of diabetes and a leading cause of end-stage renal disease. This report provides a comprehensive analysis of the market, including market size, key trends, growth drivers, challenges, and competitive landscape. Factors such as the growing diabetic population, particularly in developing countries, and the rising awareness about early diagnosis and management of diabetic kidney disease are driving the market's expansion. Additionally, the increasing focus on research and development activities to discover novel therapeutic options for the treatment of diabetic nephropathy is contributing to market growth.

Report Metric Details
Market size value in 2022 USD 2.01 billion
Market size value in 2031 USD 3.40 billion
Growth Rate 6%
Base year 2023
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Type
    • Pharmaceutical Therapy, and Renal Replacement Therapy.
  • Application
    • Hospitals, Specialty Clinics, and Others
  • Diagnostic Methods
    • Blood Tests, Urine Tests, and Imaging Techniques.
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Novartis AG (Switzerland)
  • Johnson & Johnson (US)
  • Sanofi S.A. (France)
  • AstraZeneca PLC (United Kingdom)
  • AbbVie Inc. (US)
  • Eli Lilly and Company (US)
  • Bristol Myers Squibb Company (US)
  • GlaxoSmithKline PLC (United Kingdom)
  • Novo Nordisk A/S (Denmark)
  • Bayer AG (Germany)
  • Amgen Inc. (US)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Astellas Pharma Inc. (Japan)
  • Daiichi Sankyo Company, Limited (Japan)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Fresenius Medical Care AG & Co. KGaA (Germany)
  • Otsuka Pharmaceutical Co., Ltd. (Japan)
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Diabetic Nephropathy Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Diabetic Nephropathy Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Diabetic Nephropathy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Diabetic Nephropathy Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Diabetic Nephropathy Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Diabetic Nephropathy Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?
REQUEST FREE CUSTOMIZATION

FAQs

Diabetic Nephropathy Market size was valued at USD 2.01 billion in 2022 and is poised to grow from USD 2.13 billion in 2023 to USD 3.40 billion by 2031, growing at a CAGR of 6% in the forecast period (2024-2031).

The global diabetic nephropathy market is characterised by intense competition among key players aiming to capture a significant market share. Diabetic nephropathy refers to kidney damage caused by diabetes, and the market encompasses a wide range of treatment options, including medications, dialysis, and kidney transplant. This competitive landscape provides a general overview of the market dynamics without mentioning any specific company names. 'Novartis AG (Switzerland)', 'Merck & Co., Inc. (US)', 'Pfizer Inc. (US)', 'Johnson & Johnson (US)', 'Sanofi S.A. (France)', 'AstraZeneca PLC (United Kingdom)', 'Boehringer Ingelheim International GmbH (Germany)', 'AbbVie Inc. (US)', 'Eli Lilly and Company (US)', 'Bristol Myers Squibb Company (US)', 'GlaxoSmithKline PLC (United Kingdom)', 'Novo Nordisk A/S (Denmark)', 'Bayer AG (Germany)', 'Amgen Inc. (US)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Astellas Pharma Inc. (Japan)', 'Daiichi Sankyo Company, Limited (Japan)', 'Mitsubishi Tanabe Pharma Corporation (Japan)', 'Fresenius Medical Care AG & Co. KGaA (Germany)', 'Otsuka Pharmaceutical Co., Ltd. (Japan)'

The escalating healthcare expenditure, particularly in emerging economies, significantly contributes to the expansion of the diabetic nephropathy market. Increased healthcare funding enables enhanced accessibility to healthcare facilities, diagnostics, medications, and treatment options for individuals with diabetic nephropathy.

Development of New and More Effective Treatments: The rising cost of healthcare, and the growing demand for personalised medicine stands as key market trends. As the market continues to grow, we can expect to see more innovation in the treatment of diabetic nephropathy, and this innovation is expected to help improve the lives of people with this condition.

North America holds a prominent position in the global diabetic nephropathy market. The region is characterised by well-developed electricity infrastructure, a mature market, and a high level of consumer awareness and engagement. The US and Canada are major contributors to the region's dominance, with a strong emphasis on clean energy sources, smart grid systems, and customer-centric retail electricity services. The market in North America is supported by favourable government policies, including incentives for renewable energy adoption and energy efficiency programs. Additionally, the presence of established retail electricity providers and a competitive market landscape contribute to the dominance of North America in the Global Diabetic Nephropathy market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Diabetic Nephropathy Market

Report ID: SQMIG35D2095

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE